Europeanhhm

Nuo Therapeutics' Aurix® System Included in Wound Care Advantage's Formulary

Friday, June 23, 2023

Nuo Therapeutics, Inc. is delighted to announce that Wound Care Advantage (WCA), a prominent wound care consulting firm, has added the Aurix® System to its formulary. With a focus on emerging opportunities in the evolving healthcare landscape, Nuo is a commercial stage medical device company specializing in biodynamic therapies.

Founded in 2002, Wound Care Advantage (WCA) has established a strong network of successful wound healing programs in collaboration with partner hospitals. Their commitment to quality care and innovation has resulted in financially sustainable wound care programs that have positively impacted the lives of over 40,000 patients suffering from chronic wounds.

Dave Hazard, Nuo's Vice President of Sales, highlighted the complexities faced by wound care centers in treating diabetic foot ulcers, both clinically and financially. He expressed enthusiasm for the partnership with Wound Care Advantage, recognizing their rigorous evaluation process for products included in the formulary. This ensures that the products not only meet Medicare reimbursement criteria but also deliver effective healing outcomes.

The Aurix System's Platelet Rich Plasma gel, which is FDA-cleared for treating chronic wounds, offers a streamlined one-minute spin process. In a clinical study conducted in collaboration with the Centers for Medicare and Medicaid Services (CMS), the Aurix System demonstrated superior healing rates and significant advantages in time to heal when compared to other advanced healing modalities.

https://nuo-therapeutics-inc.ir.rdgfilings.com/press-release/

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024